Company intelligence / Profile preview

Neurotrade

Alpharetta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

NeuroTrauma Sciences (NTS) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) injuries, including traumatic brain injury (TBI) and stroke. The company was originally founded as NeuroTrade, Inc. to commercialize research from the Henry Ford Health System, focusing on neuroprotective and neurorestorative mechanisms. Its lead candidate, NTS-104, is a proprietary small molecule prodrug of a neurosteroid designed to address the complex pathophysiology of neurotrauma. Additionally, NTS is advancing a proprietary exosome-based platform derived from mesenchymal stem cells to promote brain repair and functional recovery.

Therapeutic areas: Neurology
Modalities: Small moleculeExosome-based therapy
Industry: Biotech

Partnerships

Henry Ford Health System

Beyond the preview

Go deeper on Neurotrade.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurotrade.

Explore the full profile